Translating Induced Proximity, AutoTAC, PROTAC & Other TPDs Into the Clinic to Target Neurodegeneration & Neuro-Oncology
With this ever-progressing field in neurodegenerative disease drug development, the design of protein degradation therapies has gained huge amounts of momentum. With the first patient dosed by Arvinas, the movement towards clinic has rapidly changed the focus of the field towards translating towards Phase I trials.
Be a part of the future of protein degradation for CNS diseases by keeping your knowledge up-to-date at the 2nd Protein Degradation for CNS Summit, returning to Boston for its 2nd year running. Hear the latest findings in degrader design, target identification, mechanism selection and PKPD considerations at this industry-leading conference, with expert speakers from Arvinas, Biogen and Monte Rosa Therapeutics.
Download the Full Event Guide for more information on:
- 20+ Biotech & Pharma Speakers
- 4 Interactive Deep-Dive Workshops
- 6+ Hours of Networking
- & Much More!
Emiliano Biasini
Co-Founder (Sibylla,) & Associate Professor
Centre for Integrative Biology (Cibio), University of Trento
Why Join Us?
20 speakers from leading companies in the industry, including Christopher Hickey, Associate Director, Arvinas who this year initiated the first Phase I clinical and Chang Hoon Ji, Chief Technology Officer, AUTOTAC Bio who are about to commence an in-human trial.
In depth discussions on designing optimised degraders, PK/PD considerations and the movement towards clinic. Discover the latest breakthroughs in protein degradation technology, including novel targets and mechanisms, with a focus on CNS drug discovery.
New year, New data: Many companies will be sharing their new or unpublished data! From Biogen to the Targeted Protein Degradation Centre, hear about the latest results that can shape the way protein degradation drugs are developed in the future.
Agenda Highlights:
PROTAC LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for Neurodegenerative Diseases.
Christopher Hickey, Associate Director, Arvinas
Designing, Constructing, & Screening Molecular Glue Libraries to Identify Potent & Selective Glues for Neurodegenerative Targets.
Magnus Walter,
Senior Vice President Drug Discovery, Monte Rosa Therapeutics
Focused Ultrasound-Mediated Blood Brain Barrier Opening to Enhance Drug Delivery.
Jessica Foley, Managing Director & Chief Scientific Officer, Focused Ultrasound Foundation
Evaluating the Progress in PK/PD Research for Optimising Drug Efficacy to Enhance the Translation of Therapies for CNS Diseases.
Patrick Wen, Professor of Neurology, Harvard University & Director of the Dana Faber Cancer Institute
Companies Who Attended:
Our 2025 Partners:
Partnership Opportunities:
Partnering with this summit is the perfect opportunity to position your company’s services and expertise in front of senior decision-makers and become the go-to provider for the industry.
Interested in learning more?
Testimonial:
“The pre-conference day was very useful in introducing both protein degradation and CNS basics to those new to both areas. The breadth and diversity of presentations was outstanding. The level of questions and networking was very educational” Origami Therapeutics
Origami Therapeutics
Other Events in the Series:
